Clinical trials: Apatinib
Gastrointestinal Cancer, Immunotherapy
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal
At present, surgery, radiotherapy and chemotherapy are the main treatment methods for patients with advanced gastrointestinal cancer.
- Conditions
- Gastrointestinal Cancer, Immunotherapy, Targeted Therapy
- Trial name
- NCT05225844
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Harbin Medical University
Effect of Drug, Toxicity, Drug
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic polychemotherapy followed by local surgical therapy and then postoperative (adjuvant) chemotherapy, long-term, disease-free survival can be…
- Conditions
- Effect of Drug, Toxicity, Drug, Secondary Resistance
- Trial name
- NCT04690231
- Testing
- Apatinib Mesylate, ifosfamide and etoposide
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Peking University People's Hospital
Solid Tumor
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.
- Trial name
- NCT04569916
- Testing
- radiotherapy, irinotecan liposome, apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Intrahepatic Cholangiocarcinoma (Icc)
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study
This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors.
- Trial name
- NCT07640048
- Testing
- Adebrelimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Carcinoma
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT00970138
- Testing
- apatinib tablet
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Gastric Cancer, AFP
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of PD-1 antibody combined with apatinib mesylate in patients with unresectable, local advanced recurrent or metastatic serum AFP-elevated gastric adenocarcinoma…
- Trial name
- NCT04006821
- Testing
- PD-1 antibody, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Head and Neck Neoplasms
The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer
This is a Single-center, Open-label, Single-arm, Phase Ⅱ exploratory clinical trial evaluating the efficacy and safety of Apatinib plus S1 for patients with advanced (unresectable, locally advanced, recurrent or metastatic)…
- Trial name
- NCT02943252
- Testing
- Apatinib, S1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
The development of anti-angiogenesis drugs has led to renewed enthusiasm in lung cancer treatments. Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor…
- Trial name
- NCT02515435
- Testing
- apatinib single agent
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji University
Hepatic Metastasis of Colorectal Cancer
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
- Trial name
- NCT04202978
- Testing
- Camrelizumab, Apatinib Mesylate, Capecitabine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhongshan Hospital Xiamen University
Relapsed Ovarian Cancer
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in…
- Trial name
- NCT05479487
- Testing
- Fluzoparib+Apatinib, Fluzoparib Monotherapy
- Volunteers
- 132 people
- Sponsor
- Xiaohua Wu MD
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment
This study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative…
- Trial name
- NCT03650738
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Nasopharyngeal Neoplasms
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib as maintenace therapy for Nasopharyngeal Carcinoma With Metastasis after Chemoradiotherapy, including progress free survival(PFS)、overall survival (OS)、Quality of life…
- Trial name
- NCT03180476
- Testing
- Apatinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Colorectal Cancer
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.
- Trial name
- NCT03397199
- Testing
- Apatinib + S-1
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
HER2, Advanced Gastric Cancer
Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
The goal of this observational study is to learn about in describe treatment pattern and clinical outcomes in patients with HER2-overexpressed advanced solid tumors after progression of first-line standard therapy.
- Conditions
- HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05649163
- Testing
- Disitamab Vedotin
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Shen Lin
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL
The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib, pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line treatment in patients with de novo stage IE/IIE…
- Trial name
- NCT04366128
- Testing
- CAPA indution immunotherapy
- Where
- 3 sites in China
- Volunteers
- 61 people
- Sponsor
- Rong Tao
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination…
- Trial name
- NCT05156970
- Testing
- Camrelizumab, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Intrahepatic Cholangiocarcinoma
HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05400902
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Binkui Li
Lung Cancer
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer
Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients.
- Trial name
- CCA-MPLC (NCT04201990)
- Testing
- Camrelizumab and Apatinib
- Volunteers
- 20 people
- Sponsor
- ShiYue Li
Ovarian Cancer, Triple Negative Breast Cancer
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor.
- Trial name
- NCT03075462
- Testing
- Fluzoparib, Apatinib
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Head and Neck Squamous Cell Carcinoma
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who…
- Trial name
- IMplus (NCT04440917)
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University